¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2023 ¼ºÀα޼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö : 2023-10-14

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

2023 ¼ºÀα޼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö : 2023-10-14
±³À°ÀÏÀÚ : 2023-10-14
±³À°Àå¼Ò : °æÁÖ È­¹éÄÁº¥¼Ç¼¾ÅÍ

±³À°ÁÖÁ¦ : 2023 ¼ºÀα޼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö

ÁÖÃÖ±â°ü : ´ëÇÑÇ÷¾×ÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : ¼Ò¾Æ±Þ¼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸

´ã´çÀÚ : ±èÇýÁø
¿¬¶ôó : 02-516-6581

À̸ÞÀÏ : hematology@kams.or.kr

±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, Áø´Ü°Ë»çÀÇÇаú

Âü¼®¿¹»óÀÎ : 50¸í
Èñ¸ÁÆòÁ¡ : 4Á¡

Áö¿ª : °æ»óºÏµµ
±³À°½Ã°£ : 4 ½Ã°£ 0ºÐ

¼¼ºÎ¼ö°­·á : 0¿ø  

ºñ°í


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 10¿ù 14ÀÏ 101 10:00~10:30 MRD(minimal residual disease) diagnostic technique in adult ALL(acute lymphoblastic leukemia)                          ÀÌÁö¼ö(¼­¿ïÀÇ´ë )

±³À°½Ã°£ 10¿ù 14ÀÏ 101 10:30~11:00 MRD(minimal residual disease)-based treatment approach: real world experience Á¤Çظ²(¿¬¼¼ÀÇ´ë )

±³À°½Ã°£ 10¿ù 14ÀÏ 101 11:10~11:40 Recent advances in immunotherapy & CAR-T in ALL(acute lymphoblastic leukemia) À±ÀçÈ£(°¡Å縯ÀÇ´ë )

±³À°½Ã°£ 10¿ù 14ÀÏ 101 11:40~12:10 Optimal sequencing treatment for relapsed ALL(acute lymphoblastic leukemia ) ÀÌÁöÇö(µ¿¾ÆÀÇ´ë )

±³À°½Ã°£ 10¿ù 14ÀÏ 101 13:10~13:40 "Clinical impacts of the concomitant use of L-asparaginase and total parenteral nutrition in ALL(acute lymphoblastic leukemia)  patients " °í¹Î¿À(¼­¿ï´ë¾à)

±³À°½Ã°£ 10¿ù 14ÀÏ 101 13:40~14:10 Recent update of antibody-based chemotherapy in newly diagnosed adult ALL(acute lymphoblastic leukemia) ¹éµ¿¿ø(°æºÏÀÇ´ë )

±³À°½Ã°£ 10¿ù 14ÀÏ 101 14:10~14:40 CNS(central nervous system) Relapse in adult ALL(acute lymphoblastic leukemia) patients ÀÌÁ¾Çõ(°¡Å縯ÀÇ´ë )

±³À°½Ã°£ 10¿ù 14ÀÏ 101 15:00~15:30 "Phase II trial of Rituximab preconditioning for relapsed/refractory B-cell ALL treated with blinatumomab (RICOBAL) " º¯ÀÚ¹Î(¼­¿ïÀÇ´ë )

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2023 ¼ºÀα޼º¸²ÇÁ¸ð±¸¹éÇ÷º´¿¬±¸È¸ Ãß°è ½ÉÆ÷Áö¾ö : 2023-10-14""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Çѱ¹À¯¹æ¾ÏÇÐȸ 2023 Ãß°èÇмú´ëȸ : 2023-10-14
´ÙÀ½±Û Á¦19ȸ Çѱ¹ÀÓ»ó½Ã°¢Àü±â»ý¸®ÇÐȸ Á¤±â½ÉÆ÷Áö¾ö : 2023-10-14
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20604 °­¿ø Á¦171ȸ ÇѸ²´ëÇб³Ãáõ¼º½Éº´¿ø ¼ÒÈ­±â ¿¬¼ö±³À° : 2024-06-19 0 92 2024-04-29
20603 °æ±â Á¦16ȸ ±¹¸³¾Ï¼¾ÅÍ ±¹Á¦½ÉÆ÷Áö¾ö : 2024-06-19 0 91 2024-04-29
20602 ¼­¿ï ´ëÇѽÅÀåÇÐȸ APCN & KSN 2024 4ÀÏÂ÷ : 2024-06-16 0 54 2024-04-29
20601 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-06-16 0 60 2024-04-29
20600 ¼­¿ï 2024 Á¦ 2ȸ ¿¬¼¼´ëÇб³ ¼öºÎ ¹× »óÁö ½ÉÆ÷Áö¾ö : 2024-06-16 0 67 2024-04-29
20599 ¼­¿ï ´ëÇÑ»êºÎÀΰú³»ºÐºñÇÐȸ ¿¬¼ö°­Á : 2024 »êºÎÀΰú¹Ì¼º³â¿¬¼ö°­Á : 2024-06-16 0 94 2024-04-29
20598 ±¤ÁÖ 2024³â ´ëÇÑ°ñ´Ù°øÁõÇÐȸ È£³² ¹× Á¦ÁÖ ¿¬¼ö°­Á : 2024-06-16 0 50 2024-04-29
20597 ¼­¿ï À¯¹æ ÃÊÀ½ÆÄ °Ë»ç ÀÔ¹® ±³À°: °­ÀÇ ¹× ½Ç½À : 2024-06-16 0 65 2024-04-29
20596 ¼­¿ï ´ëÇÑ°ñ´ë»çÇÐȸ SSBH 2024 (The 12th Seoul Symposium on Bone Health)&Á¦36Â÷ Ãá°èÇмú´ëȸ 3ÀÏÂ÷ : 2024-06-15 0 62 2024-04-29
20595 ¼­¿ï ´ëÇѽÅÀåÇÐȸ APCN & KSN 2024 3ÀÏÂ÷ : 2024-06-15 0 62 2024-04-29
20594 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼ÛÆı¸ÀÇ»çȸ Ãá°è ¿Â¶óÀÎ Çмú´ëȸ (6¿ù) : 2024-06-15 0 172 2024-04-29
20593 ´ë±¸ ´ëÇѵΰæºÎ¿Ü°úÇÐȸ Daegu Head and Neck Ultrasound Symposium : 2024-06-15 0 61 2024-04-29
20592 ºÎ»ê 2024³â ºÎ»ê¿Ü°úÇÐȸ Ãá°è Çмú´ëȸ : 2024-06-15 0 54 2024-04-29
20591 ´ë±¸ ´ëÇѼҾƽÉÀåÇÐȸ Á¦15ȸ ¼Ò¾ÆÆ󵿸ưíÇ÷¾Ð ½ÉÆ÷Áö¿ò : 2024-06-14 0 94 2024-04-29
20590 ¼­¿ï ¼­¿ï¾Æ»êº´¿ø (¿Â¶óÀÎ) 6¿ù 14ÀÏ ±Ý¿äÁý´ãȸ(¸¸¼º ºÎºñµ¿¿°ÀÇ Ä¡·á) : 2024-06-14 0 72 2024-04-29
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷